Key points are not available for this paper at this time.
A huge challenge for the pharmaceutical industry is hydrophobic compounds, which affect aqueous solubility, an important measure of a medicine’s efficacy. Several approaches have been used; dendrimers are particularly noteworthy because of their long-term viability, nanoscale size, large payload capacity, and adaptable end functional groups. The unique architecture of dendrimers allows for modified medication delivery and solubility profiles, making them a powerful tool for improving the solubility of hydrophobic drugs. This marks the beginning of a new era in pharmaceutical formulations. A new era in drug formulations has begun with this. As part of this study, we synthesized third-generation hydroxyl-terminated triazine-based dendrimers by meticulously reducing chlorine groups following Michael’s addition. We intend to methodically examine the effects of various concentrations of these dendrimers on the solubility behavior of glipizide, a pharmaceutical agent with intrinsic hydrophobicity, across the first, second, and third generations (the full generation). A stimulating tale of solubility improvement emerged from our research. Glipizide’s solubility was positively correlated with the concentration and generational progression of the dendrimers. The solubility of hydrophobic drugs in water can be dramatically altered by dendrimers based on hydroxyl-terminated triazine. This field of study benefits from adding new dendrimers with each generation.
Mohammedabrar H. Malek (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: